Eli Lilly (LLY) Dividends payables (2009 - 2025)

Eli Lilly has reported Dividends payables for 17 years, with the latest figure at $1.3 billion in Q2 2025.

• For the quarter ending Q2 2025, Dividends payables rose 14.93% year-over-year to $1.3 billion; the trailing twelve-month figure through Jun 2025 stood at $1.3 billion (up 14.93% YoY), and the FY2024 full-year result was $1.3 billion, up 15.15% from the prior year.
• Dividends payables for Q2 2025 stood at $1.3 billion, roughly flat from $1.3 billion in the prior quarter.
• The five-year high for Dividends payables was $1.3 billion in Q4 2024, with the low at $770.8 million in Q2 2021.
• Historically, Dividends payables has averaged $1.1 billion across 5 years, with a median of $1.0 billion in 2022.
• Annual changes were most pronounced in 2022 — Dividends payables gained 14.45% — and 2023, when it climbed 15.19%.
• Eli Lilly's Dividends payables stood at $885.5 million in 2021, then advanced by 14.87% to $1.0 billion in 2022, then rose by 14.94% to $1.2 billion in 2023, then increased by 15.15% to $1.3 billion in 2024, then declined by 0.08% to $1.3 billion in 2025.
• The last three Dividends payables figures came in at $1.3 billion (Q2 2025), $1.3 billion (Q4 2024), and $1.2 billion (Q2 2024), per Business Quant data.